Excalibur Management Corp Has $286,000 Holdings in Organon & Co. (NYSE:OGN)

Excalibur Management Corp trimmed its stake in Organon & Co. (NYSE:OGN) by 18.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,139 shares of the company’s stock after selling 4,244 shares during the quarter. Excalibur Management Corp’s holdings in Organon & Co. were worth $286,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. Commerce Bank grew its holdings in shares of Organon & Co. by 5.5% during the 3rd quarter. Commerce Bank now owns 12,168 shares of the company’s stock valued at $233,000 after acquiring an additional 637 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after purchasing an additional 672 shares during the last quarter. Beam Wealth Advisors Inc. raised its stake in shares of Organon & Co. by 3.9% during the 4th quarter. Beam Wealth Advisors Inc. now owns 18,888 shares of the company’s stock worth $282,000 after purchasing an additional 717 shares in the last quarter. HighTower Advisors LLC lifted its holdings in shares of Organon & Co. by 0.5% during the 4th quarter. HighTower Advisors LLC now owns 163,440 shares of the company’s stock valued at $2,439,000 after buying an additional 855 shares during the last quarter. Finally, CIBC Asset Management Inc grew its stake in shares of Organon & Co. by 4.9% in the 4th quarter. CIBC Asset Management Inc now owns 25,523 shares of the company’s stock valued at $381,000 after buying an additional 1,184 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Trading Down 3.8 %

Organon & Co. stock opened at $14.74 on Wednesday. The business’s 50-day simple moving average is $15.41 and its 200-day simple moving average is $16.33. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The firm has a market capitalization of $3.80 billion, a PE ratio of 4.43, a PEG ratio of 0.90 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Equities research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 7.60%. Organon & Co.’s dividend payout ratio (DPR) is 33.63%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Barclays reduced their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Morgan Stanley cut their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Organon & Co. presently has a consensus rating of “Hold” and an average price target of $20.80.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.